Dianthus Therapeutics, Inc. /DE/DNTHEarnings & Financial Report
Nasdaq
NextMar 25, 2026
DNTH Q3 2025 Key Financial Metrics
Revenue
$396.0K
Gross Profit
N/A
Operating Profit
$-40.3M
Net Profit
$-36.8M
Gross Margin
N/A
Operating Margin
-10173.7%
Net Margin
-9284.1%
YoY Growth
-81.8%
EPS
$-0.97
Financial Flow
Dianthus Therapeutics, Inc. /DE/ Q3 2025 Financial Summary
Dianthus Therapeutics, Inc. /DE/ reported revenue of $396.0K for Q3 2025, with a net profit of $-36.8M (-9284.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $396.0K |
|---|---|
| Net Profit | $-36.8M |
| Gross Margin | N/A |
| Operating Margin | -10173.7% |
| Report Period | Q3 2025 |
Dianthus Therapeutics, Inc. /DE/ Annual Revenue by Year
Dianthus Therapeutics, Inc. /DE/ annual revenue history includes year-by-year totals (for example, 2024 revenue was $6.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $6.2M |
Income Statement
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $924000 | $874000 | $1.9M | $2.2M | $1.3M | $1.2M | $193000 | $396000 |
| YoY Growth | -21.2% | N/A | N/A | 135.1% | N/A | 33.1% | -89.6% | -81.8% |
Balance Sheet
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $192.5M | $382.5M | $369.0M | $354.2M | $374.0M | $348.6M | $326.1M | $577.4M |
| Liabilities | $14.1M | $9.8M | $10.7M | $16.4M | $21.5M | $20.0M | $23.0M | $31.0M |
| Equity | $178.4M | $372.7M | $358.2M | $337.9M | $352.5M | $328.6M | $303.1M | $546.5M |
Cash Flow
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $17.1M | $-14.9M | $-14.5M | $-21.3M | $-27.4M | $-27.6M | $-23.9M | $-30.6M |